title: Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era.
abstract: Although predictors of acute intraprocedural stent thrombosis (IPST) in the drug-eluting stent era have been proposed, external validation is lacking. We thus analyzed the occurrence of IPST in the RECIPE study and found that, among 1,320 patients who underwent drug-eluting stent implantation, IPST occurred in 6 (0.5%), with in-hospital major adverse events in 4 (67%). IPST was predicted by number and total length of implanted stents, baseline minimal lumen diameter, and, in a pooled analysis that incorporated values from the present study and a previous study, use of elective glycoprotein IIb/IIIa inhibitors. Such results may provide useful information to guide prevention of this complication.
authors.affiliation: St. Raffaele Hospital, Milan, Italy.
authors.forename: Giuseppe G L
authors.initials: GG
authors.lastname: Biondi-Zoccai
authors.forename: Giuseppe M
authors.initials: GM
authors.lastname: Sangiorgi
authors.forename: Alaide
authors.initials: A
authors.lastname: Chieffo
authors.forename: Guido
authors.initials: G
authors.lastname: Vittori
authors.forename: Elena
authors.initials: E
authors.lastname: Falchetti
authors.forename: Massimo
authors.initials: M
authors.lastname: Margheri
authors.forename: Rossella
authors.initials: R
authors.lastname: Barbagallo
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
authors.forename: Enrico
authors.initials: E
authors.lastname: Remigi
authors.forename: Carlo
authors.initials: C
authors.lastname: Briguori
authors.forename: Ioannis
authors.initials: I
authors.lastname: Iakovou
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Agostoni
authors.forename: Elephteria
authors.initials: E
authors.lastname: Tsagalou
authors.forename: Gloria
authors.initials: G
authors.lastname: Melzi
authors.forename: Iassen
authors.initials: I
authors.lastname: Michev
authors.forename: Flavio
authors.initials: F
authors.lastname: Airoldi
authors.forename: Matteo
authors.initials: M
authors.lastname: Montorfano
authors.forename: Mauro
authors.initials: M
authors.lastname: Carlino
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
mesh_terms: D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D000077144:Clopidogrel; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000601:surgery; D003328:Coronary Thrombosis / Q000175:diagnosis* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007431:Intraoperative Complications; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011725:Pyridines / Q000627:therapeutic use; D012189:Retrospective Studies; D015607:Stents; D015912:Thrombolytic Therapy; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C446540:thienopyridine; D006493:Heparin; D000077144:Clopidogrel; D013988:Ticlopidine; D017239:Paclitaxel